Generation Bio Announced Development Of Immune-Quiet DNA; Systemic Administration With Generation Bio's Lipid Nanoparticle Delivery Has Shown Cytokine Levels And Tolerability Comparable To Chemically Modified Messenger RNA In Mice, Non-human Primates
Portfolio Pulse from Benzinga Newsdesk
Generation Bio has announced the development of an immune-quiet DNA, which when administered systemically with the company's lipid nanoparticle delivery, has shown cytokine levels and tolerability comparable to chemically modified messenger RNA in mice and non-human primates.
October 18, 2023 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The development of an immune-quiet DNA by Generation Bio could potentially enhance the company's product portfolio and competitiveness in the biotech industry.
The development of an immune-quiet DNA, which shows comparable results to chemically modified mRNA, could potentially enhance Generation Bio's product portfolio and competitiveness in the biotech industry. This could lead to increased investor interest and a potential rise in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100